Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations

NCT07670156 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

JAK1 GOF
STAT1 GOF
STAT3 GOF
STAT5B GOF
STAT6 GOF

Interventions

DRUG: Upadacitinib
DRUG: Placebo

Sponsor

Lisa Satter

Collaborators

[object Object]
[object Object]